Data / Companies / RAPP
Rapport Therapeutics, Inc.Nasdaq
RAPP-US · CIK 0002012593 · Pharmaceutical Preparations
Revenue by quarter
US$ · last 8Hover a column for its exact figure
$0$5M$10M$15M$20M
Q1 '25Q2 '25Q1 '26Q2 '26
| Quarter | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$56.6M | -1.19 |
| Q1 FY2026 | $20.0M | -$19.9M | -0.42 |
| Q2 FY2025 | $0 | -$26.7M | -0.75 |
| Q1 FY2025 | $0 | -$24.1M | -0.68 |
Newest filings
All 68| Form | Filed | Accepted (ET) | |
|---|---|---|---|
| 305B2 | 29 Oct 2026 | 29 Oct, 4:06 PM | |
| 8-K | 20 Oct 2026 | 20 Oct, 6:05 AM | |
| 10-Q | 5 Aug 2026 | ||
| 8-K | 5 Aug 2026 | ||
| 8-K | 10 Jun 2026 | ||
| 10-Q | 7 May 2026 | ||
| 8-K | 7 May 2026 | ||
| ARS | 23 Apr 2026 |
Description
- Ticker
- RAPP-US
- Exchange
- Nasdaq
- Index
- –
- Industry
- Pharmaceutical Preparations
- SIC division
- Manufacturing
- CIK
- 0002012593
- Fiscal year ends
- Dec
- Filings held
- 68 since 2024
- 8-K events
- 22
- Shares short
- 3.1M, 15 Oct 2026
Financial statements
The main lines of the income statement, balance sheet and cash flow, by year and by quarter. Each period opens its filing.
0 years · US$ millions
| Fiscal period |
|---|
| Period ending |
| Reported in |
| Report filed |
Ratios
Worked out the same way for every company. Hover a ratio for how it is calculated.
Valuation
- Market cap
- $1.2B
- Price
- $24.18
- Price to book
- 2.74×
- Enterprise value
- $1.1B
- 52-week high
- $52.50
- 52-week low
- $22.49
Profitability
Growth
- Price, 1 year
- -11.7%
Balance sheet
- Cash and equivalents
- $63.6M
- Borrowings
- $0
- Net debt
- -$63.6M
- Debt to equity
- 0.00×
- Shareholders' equity
- $422.9M
- Total assets
- $459.0M
Shareholders
- Shares outstanding
- 47,955,079
- Share count, last 12 months
- 31.4%
What the company said with its results
The key points, guidance and management's own words from each of the last four results releases.
No results summary read for this company yet.
Revenue by segment
As the company reports it in the segment note of each annual report: by business, by product and by region, latest year.
This company reports no segment split in its annual report.
Company events
Every 8-K, sorted by the event it reports, with the moment the SEC accepted it in New York time.
| 20 Oct 2026 | 20 Oct, 6:05 AM ET | 8-K | Investor updateOther events | 7.01, 8.01, 9.01 | |
| 5 Aug 2026 | 8-K | Results | 2.02, 9.01 | ||
| 10 Jun 2026 | 8-K | Shareholder vote | 5.07 | ||
| 7 May 2026 | 8-K | Results | 2.02, 9.01 | ||
| 21 Apr 2026 | 8-K | Investor updateOther events | 7.01, 8.01 | ||
| 10 Mar 2026 | 8-K | Results | 2.02, 9.01 | ||
| 7 Jan 2026 | 8-K | Other events | 8.01, 9.01 | ||
| 7 Jan 2026 | 8-K | Investor updateOther events | 7.01, 8.01, 9.01 | ||
| 6 Nov 2025 | 8-K | Results | 2.02, 9.01 | ||
| 10 Sep 2025 | 8-K | Material agreement | 1.01, 9.01 | ||
| 8 Sep 2025 | 8-K | Other events | 8.01, 9.01 | ||
| 8 Sep 2025 | 8-K | Investor updateOther events | 7.01, 8.01, 9.01 | ||
| 7 Aug 2025 | 8-K | ResultsInvestor update | 2.02, 7.01, 9.01 | ||
| 18 Jun 2025 | 8-K | Shareholder vote | 5.07 | ||
| 2 Jun 2025 | 8-K | Investor updateOther events | 7.01, 8.01, 9.01 | ||
| 8 May 2025 | 8-K | Results | 2.02, 9.01 | ||
| 11 Mar 2025 | 8-K | Results | 2.02, 9.01 | ||
| 3 Mar 2025 | 8-K | Investor updateOther events | 7.01, 8.01, 9.01 | ||
| 10 Jan 2025 | 8-K | Investor updateOther events | 7.01, 8.01, 9.01 | ||
| 7 Nov 2024 | 8-K | Results | 2.02, 9.01 | ||
| 8 Aug 2024 | 8-K | Results | 2.02, 9.01 | ||
| 10 Jun 2024 | 8-K | Material agreementShare saleBylaws or fiscal year change | 1.01, 3.02, 5.03, 9.01 |
8-K events each year
Hover a column for its exact count
051015
'24'26
Every filing
The company's filings with the SEC, newest first: 68 held. Insider, fund and large-holder filings have their own tables below.
| 29 Oct 2026 | 305B2 | – | 29 Oct, 4:06 PM ET | |
| 20 Oct 2026 | 8-K | 20 Oct 2026 | 20 Oct, 6:05 AM ET | |
| 5 Aug 2026 | 10-Q | 30 Jun 2026 | ||
| 5 Aug 2026 | 8-K | 5 Aug 2026 | ||
| 10 Jun 2026 | 8-K | 10 Jun 2026 | ||
| 7 May 2026 | 10-Q | 31 Mar 2026 | ||
| 7 May 2026 | 8-K | 7 May 2026 | ||
| 23 Apr 2026 | ARS | 31 Dec 2025 | ||
| 23 Apr 2026 | DEFA14A | – | ||
| 23 Apr 2026 | DEF 14A | 10 Jun 2026 | ||
| 21 Apr 2026 | 8-K | 21 Apr 2026 | ||
| 10 Mar 2026 | S-3ASR | – | ||
| 10 Mar 2026 | S-8 | – | ||
| 10 Mar 2026 | 10-K | 31 Dec 2025 | ||
| 10 Mar 2026 | 8-K | 10 Mar 2026 | ||
| 7 Jan 2026 | 8-K | 7 Jan 2026 | ||
| 7 Jan 2026 | 8-K | 7 Jan 2026 | ||
| 6 Nov 2025 | 10-Q | 30 Sep 2025 | ||
| 6 Nov 2025 | 8-K | 6 Nov 2025 | ||
| 10 Sep 2025 | 8-K | 9 Sep 2025 | ||
| 8 Sep 2025 | 8-K | 8 Sep 2025 | ||
| 8 Sep 2025 | 8-K | 8 Sep 2025 | ||
| 7 Aug 2025 | 10-Q | 30 Jun 2025 | ||
| 7 Aug 2025 | 8-K | 7 Aug 2025 | ||
| 9 Jul 2025 | EFFECT | – | ||
| 9 Jul 2025 | EFFECT | – | ||
| 7 Jul 2025 | CORRESP | – | ||
| 7 Jul 2025 | CORRESP | – | ||
| 7 Jul 2025 | UPLOAD | – | ||
| 7 Jul 2025 | UPLOAD | – | ||
| 1 Jul 2025 | S-3 | – | ||
| 1 Jul 2025 | S-3 | – | ||
| 18 Jun 2025 | 8-K | 17 Jun 2025 | ||
| 2 Jun 2025 | 8-K | 2 Jun 2025 | ||
| 8 May 2025 | 10-Q | 31 Mar 2025 | ||
| 8 May 2025 | 8-K | 8 May 2025 | ||
| 24 Apr 2025 | ARS | 31 Dec 2024 | ||
| 24 Apr 2025 | DEFA14A | – | ||
| 24 Apr 2025 | DEF 14A | 17 Jun 2025 | ||
| 11 Mar 2025 | S-8 | – | ||
| 11 Mar 2025 | 10-K | 31 Dec 2024 | ||
| 11 Mar 2025 | 8-K | 11 Mar 2025 | ||
| 3 Mar 2025 | 8-K | 3 Mar 2025 | ||
| 10 Jan 2025 | 8-K | 9 Jan 2025 | ||
| 7 Nov 2024 | 10-Q | 30 Sep 2024 | ||
| 7 Nov 2024 | 8-K | 7 Nov 2024 | ||
| 8 Aug 2024 | 10-Q | 30 Jun 2024 | ||
| 8 Aug 2024 | 8-K | 8 Aug 2024 | ||
| 26 Jul 2024 | SEC STAFF LETTER | – | ||
| 10 Jun 2024 | 8-K | 6 Jun 2024 |
1–50 of 68
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months, with the shares they held after.
| 23 Oct 2026 | Sanchez RamiroDirector | Purchase | 3,600 | $27.35 | $98.5K | 3,600 | 23 Oct 2026 |
| 21 Oct 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 2,210 | $29.16 | $64.4K | 450,035 | 23 Oct 2026 |
| 22 Oct 2026 | Silva Paul MDirector | Purchase | 3,680 | $27.07 | $99.6K | 3,680 | 22 Oct 2026 |
| 22 Oct 2026 | Young Wendy B.Director | Purchase | 3,789 | $26.39 | $100.0K | 13,289 | 22 Oct 2026 |
| 22 Oct 2026 | Paul Steven MDirector | Purchase | 35,714 | $27.28 | $974.3K | 77,380 | 22 Oct 2026 |
| 22 Oct 2026 | Maraganore JohnDirector | Purchase | 8,239 | $26.38 | $217.3K | 8,239 | 22 Oct 2026 |
| 22 Oct 2026 | Maraganore JohnDirector | Purchase | 1,172 | $26.92 | $31.5K | 9,411 | 22 Oct 2026 |
| 21 Oct 2026 | Ignelzi Troy A.Chief Financial Officer | Purchase | 5,500 | $26.10 | $143.6K | 15,500 | 21 Oct 2026 |
| 7 Oct 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 1,147 | $30.66 | $35.2K | 452,245 | 8 Oct 2026 |
| 6 Oct 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 3,375 | $32.03 | $108.1K | 453,392 | 8 Oct 2026 |
| 30 Sep 2026 | Gault CherylChief Operating Officer | Sale under a trading plan | 7,925 | $33.04 | $261.8K | 141,989 | 1 Oct 2026 |
| 30 Sep 2026 | Gault CherylChief Operating Officer | Sale under a trading plan | 2,075 | $33.76 | $70.0K | 139,914 | 1 Oct 2026 |
| 23 Sep 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 1,952 | $39.05 | $76.2K | 457,025 | 24 Sep 2026 |
| 23 Sep 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 215 | $39.86 | $8.6K | 456,810 | 24 Sep 2026 |
| 23 Sep 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 43 | $41.05 | $1.8K | 456,767 | 24 Sep 2026 |
| 8 Sep 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 7,141 | $45.55 | $325.3K | 460,046 | 9 Sep 2026 |
| 8 Sep 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 1,069 | $46.01 | $49.2K | 458,977 | 9 Sep 2026 |
| 25 Aug 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 18,921 | $49.57 | $938.0K | 467,187 | 26 Aug 2026 |
| 25 Aug 2026 | Yeleswaram KrishnaswamyChief Development Officer | Sale under a trading plan | 20,799 | $50.31 | $1.0M | 212,063 | 26 Aug 2026 |
| 25 Aug 2026 | Yeleswaram KrishnaswamyChief Development Officer | Sale under a trading plan | 16,201 | $51.06 | $827.2K | 195,862 | 26 Aug 2026 |
| 24 Aug 2026 | Yeleswaram KrishnaswamyChief Development Officer | Sale under a trading plan | 13,160 | $50.00 | $658.0K | 232,862 | 26 Aug 2026 |
| 19 Aug 2026 | Yeleswaram KrishnaswamyChief Development Officer | Sale under a trading plan | 404 | $49.90 | $20.2K | 246,022 | 20 Aug 2026 |
| 11 Aug 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 3,664 | $46.90 | $171.8K | 511,402 | 12 Aug 2026 |
| 11 Aug 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 19,500 | $48.04 | $936.8K | 491,902 | 12 Aug 2026 |
| 11 Aug 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 5,794 | $48.62 | $281.7K | 486,108 | 12 Aug 2026 |
| 10 Aug 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 14,171 | $45.97 | $651.5K | 523,436 | 12 Aug 2026 |
| 10 Aug 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 8,370 | $46.75 | $391.3K | 515,066 | 12 Aug 2026 |
| 27 Jul 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 2,203 | $42.11 | $92.8K | 537,614 | 29 Jul 2026 |
| 27 Jul 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 7 | $42.73 | $299 | 537,607 | 29 Jul 2026 |
| 14 Jul 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 5,481 | $39.72 | $217.7K | 542,546 | 15 Jul 2026 |
| 14 Jul 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 2,729 | $40.57 | $110.7K | 539,817 | 15 Jul 2026 |
| 30 Jun 2026 | Gault CherylChief Operating Officer | Sale under a trading plan | 1,900 | $40.09 | $76.2K | 158,014 | 1 Jul 2026 |
| 30 Jun 2026 | Gault CherylChief Operating Officer | Sale under a trading plan | 3,792 | $41.39 | $157.0K | 154,222 | 1 Jul 2026 |
| 30 Jun 2026 | Gault CherylChief Operating Officer | Sale under a trading plan | 3,308 | $42.17 | $139.5K | 150,914 | 1 Jul 2026 |
| 30 Jun 2026 | Gault CherylChief Operating Officer | Sale under a trading plan | 1,000 | $43.15 | $43.2K | 149,914 | 1 Jul 2026 |
| 29 Jun 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 7,344 | $39.77 | $292.1K | 548,903 | 1 Jul 2026 |
| 29 Jun 2026 | Ceesay AbrahamChief Executive Officer | Sale under a trading plan | 876 | $40.34 | $35.3K | 548,027 | 1 Jul 2026 |
| 26 May 2026 | Third Rock Ventures V, L.P.10% owner | Sale under a trading plan | 18,572 | $40.05 | $743.8K | 6,280,525 | 28 May 2026 |
| 11 May 2026 | Third Rock Ventures V, L.P.10% owner | Sale under a trading plan | 133,618 | $40.24 | $5.4M | 6,299,097 | 13 May 2026 |
| 8 May 2026 | Third Rock Ventures V, L.P.10% owner | Sale under a trading plan | 5,018 | $40.31 | $202.3K | 6,432,715 | 11 May 2026 |
| 7 May 2026 | Third Rock Ventures V, L.P.10% owner | Sale under a trading plan | 271,495 | $40.12 | $10.9M | 6,437,733 | 11 May 2026 |
| 17 Apr 2026 | Third Rock Ventures V, L.P.10% owner | Sale under a trading plan | 426,005 | $40.32 | $17.2M | 6,709,228 | 21 Apr 2026 |
| 17 Apr 2026 | Yeleswaram KrishnaswamyChief Development Officer | Sale under a trading plan | 20,225 | $39.99 | $808.8K | 246,426 | 21 Apr 2026 |
| 14 Apr 2026 | Yeleswaram KrishnaswamyChief Development Officer | Sale under a trading plan | 10,200 | $35.08 | $357.8K | 266,651 | 14 Apr 2026 |
| 13 Apr 2026 | Yeleswaram KrishnaswamyChief Development Officer | Sale under a trading plan | 9,165 | $34.97 | $320.5K | 276,851 | 14 Apr 2026 |
| 10 Apr 2026 | Yeleswaram KrishnaswamyChief Development Officer | Sale under a trading plan | 500 | $34.98 | $17.5K | 286,016 | 14 Apr 2026 |
| 8 Apr 2026 | Yeleswaram KrishnaswamyChief Development Officer | Sale under a trading plan | 360 | $34.90 | $12.6K | 286,516 | 9 Apr 2026 |
| 30 Mar 2026 | Gault CherylChief Operating Officer | Sale under a trading plan | 7,161 | $28.04 | $200.8K | 162,753 | 31 Mar 2026 |
| 30 Mar 2026 | Gault CherylChief Operating Officer | Sale under a trading plan | 2,839 | $28.55 | $81.1K | 159,914 | 31 Mar 2026 |
| 25 Mar 2026 | Yeleswaram KrishnaswamyChief Development Officer | Sale under a trading plan | 10,115 | $29.99 | $303.4K | 286,876 | 26 Mar 2026 |
1–50 of 79
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| 6 Oct 2026 | Abraham N. CeesayOfficer | 39,470 | $1.2M | 6 Oct 2026 |
| 30 Sep 2026 | CHERYL GAULTOfficer | 10,000 | $330.2K | 30 Sep 2026 |
| 25 Aug 2026 | KRISHNASWAMY YELESWARAMOfficer | 37,000 | $1.8M | 25 Aug 2026 |
| 24 Aug 2026 | KRISHNASWAMY YELESWARAMOfficer | 11,472 | $553.4K | 24 Aug 2026 |
| 19 Aug 2026 | KRISHNASWAMY YELESWARAMOfficer | 2,092 | $102.5K | 19 Aug 2026 |
| 30 Jun 2026 | CHERYL GAULTOfficer | 10,000 | $403.9K | 30 Jun 2026 |
| 29 Jun 2026 | Abraham N. CeesayOfficer | 99,480 | $4.0M | 29 Jun 2026 |
| 27 May 2026 | Third Rock Ventures V, L.P.10% Stockholder | 18,572 | $742.9K | 26 May 2026 |
| 11 May 2026 | Third Rock Ventures V, L.P.10% Stockholder | 133,618 | $5.4M | 11 May 2026 |
| 8 May 2026 | Third Rock Ventures V, L.P.10% Stockholder | 5,018 | $202.3K | 8 May 2026 |
| 7 May 2026 | Third Rock Ventures V, L.P.10% Stockholder | 271,495 | $10.9M | 7 May 2026 |
| 17 Apr 2026 | KRISHNASWAMY YELESWARAMOfficer | 20,225 | $799.7K | 17 Apr 2026 |
| 17 Apr 2026 | Third Rock Ventures V, L.P.10% Stockholder | 426,005 | $17.2M | 17 Apr 2026 |
| 13 Apr 2026 | KRISHNASWAMY YELESWARAMOfficer | 19,365 | $661.7K | 13 Apr 2026 |
| 10 Apr 2026 | KRISHNASWAMY YELESWARAMOfficer | 500 | $17.1K | 10 Apr 2026 |
| 8 Apr 2026 | KRISHNASWAMY YELESWARAMOfficer | 360 | $12.1K | 8 Apr 2026 |
| 30 Mar 2026 | CHERYL GAULTOfficer | 10,000 | $278.4K | 30 Mar 2026 |
| 25 Mar 2026 | KRISHNASWAMY YELESWARAMOfficer | 10,115 | $285.7K | 25 Mar 2026 |
| 5 Mar 2026 | Gault CherylOfficer | 2,014 | $58.2K | 5 Mar 2026 |
| 15 Jan 2026 | DAVID BREDTOfficer | 17,000 | $466.1K | 15 Jan 2026 |
| 2 Jan 2026 | Krishnaswamy YeleswaramOfficer | 2,840 | $85.3K | 2 Jan 2026 |
| 2 Jan 2026 | DAVID BREDTOfficer | 6,567 | $197.3K | 2 Jan 2026 |
| 17 Dec 2025 | THE DOROTHY CEESAY IRREVOCABLE TRUSTDirector, Officer | 15,249 | $469.1K | 17 Dec 2025 |
| 17 Dec 2025 | ABRAHAM CEESAYDirector, Officer | 17,499 | $538.3K | 17 Dec 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| 14 Aug 2026 | Third Rock Ventures V, L.P. | 13G amended | 13.1% | 6.3M |
| 14 Aug 2026 | Cormorant Asset Management, LP | 13G amended | 5.56% | 2.7M |
| 12 Aug 2026 | Capital International Investors | 13G amended | 6.1% | 2.9M |
| 15 May 2026 | Cormorant Asset Management, LP | 13G amended | 6.19% | 3.0M |
| 17 Feb 2026 | Cormorant Asset Management, LP | 13G amended | 6.35% | 3.0M |
| 21 Jan 2026 | BlackRock, Inc. | 13G | 5.03% | 2.4M |
| 14 Nov 2025 | Cormorant Asset Management, LP | 13G amended | 6.7% | 3.2M |
Trades by members of the House
From each member's periodic transaction report: the amount is the band the report gives.
No House trades in this company.
Short interest
Shares sold short and not yet bought back, on every FINRA settlement date.
Shares short, each settlement
| 15 Oct 2026 | 3.1M | -4.46% | 11.76 |
| 30 Sep 2026 | 3.2M | +42.08% | 4.84 |
| 15 Sep 2026 | 2.2M | +0.64% | 7.91 |
| 31 Aug 2026 | 2.2M | +0.36% | 8.23 |
| 14 Aug 2026 | 2.2M | -1.01% | 7.53 |
| 31 Jul 2026 | 2.2M | -16.45% | 7.51 |
| 15 Jul 2026 | 2.7M | +19.05% | 6.13 |
| 30 Jun 2026 | 2.3M | +0.63% | 4.62 |
| 15 Jun 2026 | 2.2M | -8.69% | 7.09 |
| 29 May 2026 | 2.5M | +1.76% | 8.64 |
1–10 of 57
Funds that hold it
Every fund's holding from its latest Form 13F, largest first, with what it added or trimmed in the quarter.
Funds holding
172
quarter to 30 Jun 2026
Added or new
80
since 31 Mar 2026
Trimmed
47
in the quarter
Largest holder
FMR LLC
$298.9M
The 60 largest of 172 funds, by value
1–50 of 60
Dividends and buybacks
Dividend per share, the cash paid and the shares bought back, each fiscal year.
This company has paid no dividend in the years held.
Peers
Companies in the same industry, largest first, on the same measures.
| Company | Market value | Revenue, 12 months | Revenue growth | Operating margin | Net margin | ROE | P/E | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics, Inc.this company | $1.2B | – | – | – | – | – | – | – |
| Eli Lilly & Co. | $1.29T | $86.5B | 45.5% | – | 31.9% | 68.5% | 44.6× | – |
| Johnson & Johnson | $662.4B | $99.3B | 7.8% | – | 16.2% | 19.7% | 41.7× | – |
| AbbVie Inc. | $513.9B | $64.4B | 10.4% | 26.2% | 9.8% | – | 82.2× | 23.4× |
| Merck & Co., Inc. | $361.0B | $66.6B | 4.6% | – | 4.8% | 7.6% | 117.1× | – |
| Novartis AG | $307.3B | $54.5B | 8.4% | – | – | 30.3% | 22.5× | – |
| AstraZeneca PLC | $270.6B | $58.7B | 8.6% | 23.4% | 17.4% | 21.0% | 26.7× | – |
| Abbott Laboratories | $180.9B | $46.6B | 8.1% | 15.8% | 11.6% | 10.6% | 33.8× | 19.3× |
| Novo Nordisk A/S | $174.8B | $46.8B | 6.4% | 41.3% | 33.1% | 52.8% | 11.3× | – |
| Pfizer Inc. | $170.7B | $63.7B | -0.2% | – | 6.8% | 5.1% | 39.4× | – |
| Vertex Pharmaceuticals Inc. | $136.8B | $12.6B | 10.2% | 38.0% | 35.0% | 21.8% | 31.4× | 26.1× |
What the company does
The description for this company is being written.
Free for your personal research, with credit and a link. For API access, bulk files or commercial use, tell us what you need. The data licence